Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

Identification of common biological pathways and drug targets across multiple respiratory viruses based on human host gene expression analysis.

Smith SB, Dampier W, Tozeren A, Brown JR, Magid-Slav M.

PLoS One. 2012;7(3):e33174. doi: 10.1371/journal.pone.0033174. Epub 2012 Mar 14.

2.

Novel insights into human respiratory syncytial virus-host factor interactions through integrated proteomics and transcriptomics analysis.

Dapat C, Oshitani H.

Expert Rev Anti Infect Ther. 2016;14(3):285-97. doi: 10.1586/14787210.2016.1141676. Epub 2016 Feb 3.

3.

Drug candidates and model systems in respiratory syncytial virus antiviral drug discovery.

Heylen E, Neyts J, Jochmans D.

Biochem Pharmacol. 2017 Mar 1;127:1-12. doi: 10.1016/j.bcp.2016.09.014. Epub 2016 Sep 19. Review.

4.

Host response to respiratory bacterial pathogens as identified by integrated analysis of human gene expression data.

Smith SB, Magid-Slav M, Brown JR.

PLoS One. 2013 Sep 27;8(9):e75607. doi: 10.1371/journal.pone.0075607. eCollection 2013.

5.

The host interactome of influenza virus presents new potential targets for antiviral drugs.

Shaw ML.

Rev Med Virol. 2011 Nov;21(6):358-69. doi: 10.1002/rmv.703. Epub 2011 Aug 8. Review.

6.

Host transcription profiles upon primary respiratory syncytial virus infection.

Janssen R, Pennings J, Hodemaekers H, Buisman A, van Oosten M, de Rond L, Oztürk K, Dormans J, Kimman T, Hoebee B.

J Virol. 2007 Jun;81(11):5958-67. Epub 2007 Mar 21.

7.

Cullin E3 ligases and their rewiring by viral factors.

Mahon C, Krogan NJ, Craik CS, Pick E.

Biomolecules. 2014 Oct 13;4(4):897-930. doi: 10.3390/biom4040897. Review.

8.

Respiratory syncytial virus infection enhances Pseudomonas aeruginosa biofilm growth through dysregulation of nutritional immunity.

Hendricks MR, Lashua LP, Fischer DK, Flitter BA, Eichinger KM, Durbin JE, Sarkar SN, Coyne CB, Empey KM, Bomberger JM.

Proc Natl Acad Sci U S A. 2016 Feb 9;113(6):1642-7. doi: 10.1073/pnas.1516979113. Epub 2016 Jan 4.

9.

The C-Terminal Tail of TRIM56 Dictates Antiviral Restriction of Influenza A and B Viruses by Impeding Viral RNA Synthesis.

Liu B, Li NL, Shen Y, Bao X, Fabrizio T, Elbahesh H, Webby RJ, Li K.

J Virol. 2016 Apr 14;90(9):4369-82. doi: 10.1128/JVI.03172-15. Print 2016 May.

10.

Systems-level comparison of host-responses elicited by avian H5N1 and seasonal H1N1 influenza viruses in primary human macrophages.

Lee SM, Gardy JL, Cheung CY, Cheung TK, Hui KP, Ip NY, Guan Y, Hancock RE, Peiris JS.

PLoS One. 2009 Dec 14;4(12):e8072. doi: 10.1371/journal.pone.0008072.

11.

Hsp90 inhibitors exhibit resistance-free antiviral activity against respiratory syncytial virus.

Geller R, Andino R, Frydman J.

PLoS One. 2013;8(2):e56762. doi: 10.1371/journal.pone.0056762. Epub 2013 Feb 27.

12.

Global gene expression profiling in infants with acute respiratory syncytial virus broncholitis demonstrates systemic activation of interferon signaling networks.

Bucasas KL, Mian AI, Demmler-Harrison GJ, Caviness AC, Piedra PA, Franco LM, Shaw CA, Zhai Y, Wang X, Bray MS, Couch RB, Belmont JW.

Pediatr Infect Dis J. 2013 Feb;32(2):e68-76. doi: 10.1097/INF.0b013e318278b4b3.

PMID:
23190772
13.

Mechanism of selective inhibition of respiratory syncytial virus by a benzodithiin compound (RD3-0028).

Sudo K, Konno K, Watanabe W, Shigeta S, Yokota T.

Microbiol Immunol. 2001;45(7):531-7.

14.

The human cathelicidin LL-37 has antiviral activity against respiratory syncytial virus.

Currie SM, Findlay EG, McHugh BJ, Mackellar A, Man T, Macmillan D, Wang H, Fitch PM, Schwarze J, Davidson DJ.

PLoS One. 2013 Aug 30;8(8):e73659. doi: 10.1371/journal.pone.0073659. eCollection 2013.

15.

2'-5'-Oligoadenylate Synthetase-Like Protein Inhibits Respiratory Syncytial Virus Replication and Is Targeted by the Viral Nonstructural Protein 1.

Dhar J, Cuevas RA, Goswami R, Zhu J, Sarkar SN, Barik S.

J Virol. 2015 Oct;89(19):10115-9. doi: 10.1128/JVI.01076-15. Epub 2015 Jul 15.

16.

Inhibition of respiratory syncytial virus of subgroups A and B using deoxyribozyme DZ1133 in mice.

Zhou J, Yang XQ, Xie YY, Zhao XD, Jiang LP, Wang LJ, Cui YX.

Virus Res. 2007 Dec;130(1-2):241-8. Epub 2007 Sep 4.

PMID:
17804108
17.

Identification of broad-spectrum antiviral compounds and assessment of the druggability of their target for efficacy against respiratory syncytial virus (RSV).

Bonavia A, Franti M, Pusateri Keaney E, Kuhen K, Seepersaud M, Radetich B, Shao J, Honda A, Dewhurst J, Balabanis K, Monroe J, Wolff K, Osborne C, Lanieri L, Hoffmaster K, Amin J, Markovits J, Broome M, Skuba E, Cornella-Taracido I, Joberty G, Bouwmeester T, Hamann L, Tallarico JA, Tommasi R, Compton T, Bushell SM.

Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):6739-44. doi: 10.1073/pnas.1017142108. Epub 2011 Apr 18.

18.

Challenges and opportunities in developing respiratory syncytial virus therapeutics.

Simões EA, DeVincenzo JP, Boeckh M, Bont L, Crowe JE Jr, Griffiths P, Hayden FG, Hodinka RL, Smyth RL, Spencer K, Thirstrup S, Walsh EE, Whitley RJ.

J Infect Dis. 2015 Mar 15;211 Suppl 1:S1-S20. doi: 10.1093/infdis/jiu828.

19.

Novel anti-RSV dianionic dendrimer-like compounds: design, synthesis and biological evaluation.

Gazumyan A, Mitsner B, Ellestad GA.

Curr Pharm Des. 2000 Mar;6(5):525-46. Review.

PMID:
10788595
20.

The landscape of host transcriptional response programs commonly perturbed by bacterial pathogens: towards host-oriented broad-spectrum drug targets.

Kidane YH, Lawrence C, Murali TM.

PLoS One. 2013;8(3):e58553. doi: 10.1371/journal.pone.0058553. Epub 2013 Mar 13.

Supplemental Content

Support Center